Comparative Pharmacology
Head-to-head clinical analysis: FIRAZYR versus QBRELIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIRAZYR versus QBRELIS.
FIRAZYR vs QBRELIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Icatibant is a selective antagonist of the bradykinin B2 receptor, blocking the binding of bradykinin and thereby inhibiting the increased vascular permeability and vasodilation that underlie acute attacks of hereditary angioedema (HAE).
Angiotensin II receptor blocker; selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and decreased aldosterone secretion.
30 mg subcutaneously every 3 days. For acute attacks, 30 mg subcutaneously as needed, not to exceed 3 doses in 24 hours.
1 mg/kg intravenously or subcutaneously every 6 hours for acute attacks, maximum 3.3 mL per injection site.
None Documented
None Documented
Terminal half-life approximately 1.5 hours; clinically, effects last longer due to receptor binding kinetics.
Terminal elimination half-life is approximately 10 hours (range 7-14 hours) in healthy adults; prolonged in renal impairment.
Primarily metabolized in the liver (hydrolysis by peptidases); renal excretion of metabolites (approximately 25% unchanged drug in urine). Less than 10% excreted in feces.
Primarily renal (approximately 80%) with minimal biliary/fecal elimination (less than 5%).
Category C
Category C
Bradykinin B2 Receptor Antagonist
Bradykinin B2 Receptor Antagonist